Mr. Indrajit Banerjee (born on 14th January, 1956) joined the Board of the Company as an Independent Director on 9th February, 2021. He is an Associate member of the Institute of Chartered Accountants of India. He is a Chairman of the Audit Committee and a Member of the Nomination and Remuneration Committee and the Risk Management Committee of the Board of the Company.
He has a career spanning more than four decades. He began his career at Price Waterhouse, subsequently taking on roles in the pharmaceutical / healthcare and hydrocarbon and metal industries and later joined industry, where he built extensive experience in Finance, Strategy, Legal, Information Technology, Mergers & Acquisitions (“M&A”) and general management functions. He served as Chief Financial Officer / Executive Director in Ranbaxy, Lupin, Cairn India and Indian Aluminium Company Limited. He helped these companies transform into technologyled efficient organisations with superior competitive strength. During his professional journey, he helped companies to market changes, transform into innovative organisations, expand their market presence and create significant stakeholders value. He managed situations of high growth, mobilised large capital investment from global investors, implemented new-age ERP systems, facilitated major M&A transactions and managed integration thereafter, restructured complex organisations to achieve efficiency in capital usage and helped organisations achieve significant cost efficiency and productivity improvement.
In most of the functions that he worked in, the key business deliverable was creating globally competitive strength that helped build sustainable business. He helped create cost synergies for global operations in the pharmaceutical industry, build robust cost effective infrastructure for greenfield hydrocarbon upstream facilities, rationalised multi-unit operation to make significant improvement of productivity in marketing and supply chain functions, among others. While performing his roles in the organisations he worked for, he focused, inter alia, on establishing good corporate governance practices, re-engineering of internal processes and systems to improve financial controls, establishing reliable risk management platform, creating reliable stakeholder management processes and training and development of talent.
He is, currently, based in Gurugram and is engaged in pharmaceutical consultancy helping pharma operators to expand their global operations.
Directorship held in other body corporates as on 30th September, 2025:
| Sr. no. | Name of the Entities |
|---|---|
| 1. | Fortis Healthcare Limited |
| 2. | Fortis Hospotel Limited |
| 3. | Agilus Diagnostics Limited |
| 4. | Suingora Consulting LLP (Designated Partner) |
